Bone marrow transplantation for thalassemia

Area of Science:

• Hematology
• Transplantation Immunology

Background:

• Homozygous beta-thalassemia is a severe genetic blood disorder requiring lifelong treatment.
• Allogeneic bone marrow transplantation (BMT) has emerged as a potential curative therapy.
• Early BMT trials focused on patients under 16 years old.

Purpose of the Study:

• To identify risk factors influencing BMT outcomes in beta-thalassemia.
• To stratify patients into risk classes for optimized BMT protocols.
• To evaluate the efficacy of BMT in older patients (>16 years).

Main Methods:

• Analysis of early BMT trial data in homozygous beta-thalassemia patients.
• Development of a three-class risk stratification system based on hepatomegaly, portal fibrosis, and pre-transplant chelation quality.
• Assignment of patients to distinct BMT protocols based on risk class, irrespective of age.
• Evaluation of survival and event-free survival probabilities.

Main Results:

• Risk classes were defined: Class 1 (no adverse criteria), Class 2 (intermediate), and Class 3 (all adverse criteria).
• Patients >16 years old typically fall into Class 3.
• Survival probabilities for Class 1, 2, and 3 were 98%, 87%, and 100% respectively.
• Event-free survival probabilities for Class 1, 2, and 3 were 94%, 84%, and 67% respectively.
• For patients >16 years, survival was 82% and event-free survival was 79%.

Conclusions:

• BMT is a viable radical treatment for beta-thalassemia in patients with an HLA-identical donor.
• The developed risk stratification system effectively predicts BMT outcomes.
• Age is less critical than risk class in determining BMT success with HLA-identical donors.